Soegiarto, Gatot and Mahdi, Bagus Aulia and Wulandari, Laksmi and Fahmita, Karin Dhia and Hadmoko, Satrio Tri and Gautama, Hendra Ikhwan and Prasetyaningtyas, Dewi and Prasetyo, Muhammad Edwin and Negoro, Pujo Prawiro and Arafah, Nur and Purnomosari, Dewajani and Tinduh, Damayanti and Husada, Dominicus and Baskoro, Ari and Fetarayani, Deasy and Nurani, Wita Kartika and Oceandy, Delvac (2023) Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia. Vaccines, 11 (7). ISSN 2076393X
Full text not available from this repository. (Request a copy)Abstract
Background: The administration of the third (or booster) dose of COVID-19 vaccine is important in maintaining protection against SARS-CoV-2 infection or the severity of the disease. In Indonesia, health care workers (HCWs) are among the first to receive a booster dose of the COVID-19 vaccine. In this study, we evaluated the antibody response and adverse events following heterologous booster vaccine using mRNA-1273 among HCWs that were fully vaccinated with inactivated viral vaccine as the priming doses. Methods: 75 HCWs at Dr. Soetomo General Hospital in Surabaya, Indonesia, participated in this study. The level of antibody against the SARS-CoV-2 receptor binding domain was analyzed at 1, 3, and 5 months following the second priming dose and at 1, 3, and 5 months after the booster dose. Results: We found a significantly higher level of antibody response in subjects receiving a booster dose of the mRNA-1273 vaccine compared to those receiving an inactivated viral vaccine as a booster. Interestingly, participants with hypertension and a history of diabetes mellitus showed a lower antibody response following the booster dose. There was a higher frequency of adverse events following injection with the mRNA-1273 vaccine compared to the inactivated viral vaccine, although the overall adverse events were considered minor. Conclusions: A heterologous booster dose using mRNA vaccine resulted in a high antibody response; however, participants with hypertension and diabetes mellitus displayed a lower antibody response. © 2023 by the authors.
Item Type: | Article |
---|---|
Additional Information: | Cited by: 2; All Open Access, Gold Open Access |
Uncontrolled Keywords: | coronavac; elasomeran; immunoglobulin G; mrna 1273; adult; adverse event; allergic disease; antibody response; antibody titer; arthralgia; Article; blood pressure; cardiovascular disease; chill; cohort analysis; coronavirus disease 2019; coughing; diabetes mellitus; diarrhea; fatigue; feeding disorder; female; fever; follow up; headache; health care personnel; human; human experiment; hunger; hypertension; Indonesia; injection site pain; male; middle aged; myalgia; receptor binding; Severe acute respiratory syndrome coronavirus 2; somnolence; vaccination; vomiting |
Subjects: | R Medicine > RB Biomedical Sciences |
Divisions: | Faculty of Medicine, Public Health and Nursing > Biomedical Sciences |
Depositing User: | Sri JUNANDI |
Date Deposited: | 01 Nov 2024 03:02 |
Last Modified: | 01 Nov 2024 03:02 |
URI: | https://ir.lib.ugm.ac.id/id/eprint/6074 |